MXPA03001472A - Compuestos para el tratamiento de trastornos adictivos. - Google Patents

Compuestos para el tratamiento de trastornos adictivos.

Info

Publication number
MXPA03001472A
MXPA03001472A MXPA03001472A MXPA03001472A MXPA03001472A MX PA03001472 A MXPA03001472 A MX PA03001472A MX PA03001472 A MXPA03001472 A MX PA03001472A MX PA03001472 A MXPA03001472 A MX PA03001472A MX PA03001472 A MXPA03001472 A MX PA03001472A
Authority
MX
Mexico
Prior art keywords
compounds
treatment
addictive disorders
addictive
disorders
Prior art date
Application number
MXPA03001472A
Other languages
English (en)
Inventor
Robert C Marshall
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of MXPA03001472A publication Critical patent/MXPA03001472A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MXPA03001472A 2000-08-16 2001-08-13 Compuestos para el tratamiento de trastornos adictivos. MXPA03001472A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22571400P 2000-08-16 2000-08-16
US26361001P 2001-01-23 2001-01-23
PCT/US2001/025603 WO2002013807A2 (en) 2000-08-16 2001-08-13 Compounds for the treatment of addictive disorders

Publications (1)

Publication Number Publication Date
MXPA03001472A true MXPA03001472A (es) 2003-06-06

Family

ID=26919847

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001472A MXPA03001472A (es) 2000-08-16 2001-08-13 Compuestos para el tratamiento de trastornos adictivos.

Country Status (17)

Country Link
US (2) US6841557B2 (es)
EP (1) EP1363634A2 (es)
JP (1) JP2004506621A (es)
KR (1) KR20030024877A (es)
AR (1) AR030364A1 (es)
AU (2) AU2001283393B2 (es)
BR (1) BR0112939A (es)
CA (1) CA2413762A1 (es)
CZ (1) CZ200380A3 (es)
EA (1) EA200300271A1 (es)
IL (1) IL154378A0 (es)
MX (1) MXPA03001472A (es)
NO (1) NO20030717D0 (es)
NZ (1) NZ524741A (es)
PE (1) PE20020288A1 (es)
PL (1) PL363365A1 (es)
WO (1) WO2002013807A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
JP2006506360A (ja) * 2002-10-04 2006-02-23 ファルマシア・コーポレーション パーキンソン病の治療のための医薬組成物
ATE359075T1 (de) 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
ES2579853T3 (es) * 2010-09-20 2016-08-17 A.Carlsson Research Ab Compuestos de fenilpiperidina para el tratamiento de demencia

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
US4800204A (en) * 1987-05-07 1989-01-24 Mueller Peter S Method of controlling tobacco use
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
AU626427B2 (en) * 1989-06-09 1992-07-30 Pharmacia & Upjohn Company Heterocyclic amines having central nervous system activity
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
US5051426A (en) * 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency
EP0536279A1 (en) * 1990-06-29 1993-04-14 The Upjohn Company Substituted 1-(alkoxyphenyl)piperazines with cns and antihypertensive activity
ATE201669T1 (de) 1991-04-17 2001-06-15 Upjohn Co Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
TW252979B (es) * 1992-12-24 1995-08-01 Erba Carlo Spa
CN1046723C (zh) * 1993-04-06 1999-11-24 艾博特公司 四环化合物、含有它们的药物组合物及其用途
NZ277373A (en) 1993-12-28 1998-07-28 Upjohn Co Iso(thio)chroman-1-ylethylpiperazine and -piperidine derivatives (analogues)
GB9407637D0 (en) * 1994-04-18 1994-06-08 Erba Carlo Spa Serotoninergic abeo-ergoline derivatives
US5874477A (en) * 1994-08-12 1999-02-23 The University Of Hawaii Method of treatment for malaria utilizing serotonin receptor ligands
RU2140910C1 (ru) * 1995-08-11 1999-11-10 Пфайзер Инк. Тригидрат метансульфоната (1s,2s)-1-(4-гидроксифенил)-2-(4-гидрокси-4- фенилпиперидин-1-ил)-1-пропанола
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9603226D0 (en) * 1996-02-15 1996-04-17 Pharmacia Spa Heterocyclyl-ergoline derivatives
US6001848A (en) * 1996-03-25 1999-12-14 The Regents Of The University Of California Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele
HN1998000118A (es) * 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
GB9723544D0 (en) * 1997-11-07 1998-01-07 Merck Sharp & Dohme Therapeutic agents
WO1999036095A1 (en) * 1998-01-13 1999-07-22 Astrazeneca Uk Limited PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D2) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING β2-ADRENORECEPTOR AGONIST ACTIVITY
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
AU2001253114B2 (en) * 2000-04-21 2005-08-25 Pharmacia & Upjohn Company Llc Compounds for treating fibromyalgia and chronic fatigue syndrome

Also Published As

Publication number Publication date
AU2001283393B2 (en) 2005-09-22
IL154378A0 (en) 2003-09-17
US20020049206A1 (en) 2002-04-25
BR0112939A (pt) 2005-11-01
AR030364A1 (es) 2003-08-20
NZ524741A (en) 2005-01-28
AU8339301A (en) 2002-02-25
PE20020288A1 (es) 2002-03-31
PL363365A1 (en) 2004-11-15
CA2413762A1 (en) 2002-02-21
KR20030024877A (ko) 2003-03-26
WO2002013807A2 (en) 2002-02-21
NO20030717L (no) 2003-02-14
EA200300271A1 (ru) 2004-02-26
JP2004506621A (ja) 2004-03-04
EP1363634A2 (en) 2003-11-26
NO20030717D0 (no) 2003-02-14
US20030078273A1 (en) 2003-04-24
CZ200380A3 (cs) 2004-01-14
WO2002013807A3 (en) 2003-09-25
US6841557B2 (en) 2005-01-11

Similar Documents

Publication Publication Date Title
EP1274444A4 (en) DRUGS FOR THE TREATMENT OF PSYCHIATRICAL OR ABUSUS-RELATED DISORDER
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
ZA200202461B (en) Compounds for the treatment of ischemia.
IL209842A0 (en) Compounds for the treatment of metabolic disorders
MXPA03006250A (es) Compuestos heterociclicos terapeuticos.
HK1053058A1 (zh) 普拉克索用於治療成癮性疾病的用途
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
HK1064261A1 (en) Method for the treatment of tobacco.
MXPA03006607A (es) Metodo combinado para tratar trastornos dependientes de hormonas.
MXPA03001800A (es) Proceso para la preparacion de fenilacetonitrilos sustituidos.
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
MXPA02006102A (es) Metodo para preparar compuestos bormodifluoroaceticos.
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
MXPA03002926A (es) Proceso para la sintesis de 2,2,6,6,-tetrametil-4--oxipiperidina.
MXPA03004195A (es) Terapia combinada para los trastornos dependientes de estrogenos.
MXPA03009210A (es) PROCEDIMIENTO PARA LA PREPARACIoN DE OXABISPIDINAS.
EG23417A (en) Process for the preparation 7 a-methylsteroids.
EP1278538A4 (en) ANTIBODIES BINDING TO CD18 AND INHIBITING STENOSE-RELATED DISORDERS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal